Look like this may be a bear week due to momentum indicators coming down from above while price fell off one flight of stair. This is still too early to tell if the bull has gone into a deep sleep.
Currently, price is still above the 15, 79, & 89 MA supports. A little back & forth can be healthy as long as price doesn’t flow into the waterfall.
$DMRC did a great job today by breaking out of the downtrend line.
Price is now above the 79 & 89 MA supports. Short-term resistances from above are $38.75 and $40.20.
The close today confirmed November monthly bar as one giant bullish engulfment bar. This is very bullish especially when this comes from a monthly chart. The longer period the price bar represented, the more substantial is the signal. There is a good chance that price may take out $40.20 within two weeks.
$IBIO continued to advance with strong volume. Today news, iBio Continues Global Expansion of Intellectual Property, solidifies iBio’s IP asset and setting the stage for the fibrosis treatment with their revolutionary IBIO-CFB03. If this works, I believe there will be immediate global demand for IBIO-CFB03 since it has the potential to reverse fibrosis diseases and cancel the dead-sentence for many. Again, I couldn’t believe this is still under a buck for this stock. Needless to say, I’ve already loaded up. This is my 2nd largest position after $DMRC.
A few more up days and price will be above the 79 & 89 resistances.
$BIOC bounced back from last Friday drop which is a good sign. Biocept news today, Biocept Gains Patent Protection in Hong Kong and Japan, further expanded its IP pattern to the Far East. What I like about Biocept is its ability to attract insurance companies to cover their liquid biopsy testing. I bet their IP patents play an important role in getting medical coverage. Click here for a good summary on their patents.
Another thing I like about Biocept is its coming prostate cancer test. As most people older than 50 years will know, routine blood test includes a test for PSA level. Any number higher than 4 is an “alert” for possible cancerous prostate. But the PSA level is not a sure thing for identifying cancer, it only alerts to possible cancerous prostate. Here’s an excerpt from http://www.cancer.gov/types/prostate/psa-fact-sheet
What is a normal PSA test result?
There is no specific normal or abnormal level of PSA in the blood. In the past, most doctors considered PSA levels of 4.0 ng/mL and lower as normal. Therefore, if a man had a PSA level above 4.0 ng/mL, doctors would often recommend a prostate biopsy to determine whether prostate cancer was present.
However, more recent studies have shown that some men with PSA levels below 4.0 ng/mL have prostate cancer and that many men with higher levels do not have prostate cancer (1). In addition, various factors can cause a man’s PSA level to fluctuate. For example, a man’s PSA level often rises if he has prostatitis or a urinary tract infection. Prostate biopsies and prostate surgery also increase PSA level. Conversely, some drugs—including finasteride and dutasteride, which are used to treat BPH—lower a man’s PSA level. PSA level may also vary somewhat across testing laboratories.
Another complicating factor is that studies to establish the normal range of PSA levels have been conducted primarily in populations of white men. Although expert opinions vary, there is no clear consensus regarding the optimal PSA threshold for recommending a prostate biopsy for men of any racial or ethnic group.
In general, however, the higher a man’s PSA level, the more likely it is that he has prostate cancer. Moreover, continuous rise in a man’s PSA level over time may also be a sign of prostate cancer.
While the PSA test has its limit (see underlined), it is definitely a good starting point. However, once Biocept’s liquid biopsy for prostate cancer testing becomes the standard, it is very possible that it may completely replace the need for PSA test. Think about it, why go for, “You may have prostate cancer due to high PSA number” when you can say, “your liquid biopsy comes back positive ’cause we found the known prostate cancerous cells in your blood stream. It’s good thing we caught it early.”
As we live longer life, the world aging population (people over 50 years of age) increases year-over-year. And the need for more effective and accurate prostate cancer test becomes even more important than wasting time and money doing multiple PSA tests only to confirm the need for tissue biopsy in order to confirm actual cancerous cells before even contemplating for treatment. Did you notice how much time has been lost before treatment even begins?
That is why it is so important for Biocept to come out with their Prostate cancer test that can stand taller among competition.
Price is now back at the $1.9x trading range ready for the big POP.
$AKAO and $ARTH dropped further due to nervous hands bailing. Just because weak hands leaving doesn’t mean I’ve to follow them or be alarmed. I’m holding for the human trial for $ARTH and nothing else matter at this point.
Thanks to $DMRC, $IBIO, & $BIOC, my port recovered some more.
Main port: DMRC, IBIO, BIOC, AKAO Trading port: ARTH
My 2 cents
From my camera (click on photo to see image at 100%)